News & events

Mendus AB today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk Investments...

Mendus AB (“Mendus” publ; IMMU.ST), today announced its participation in the following upcoming investor and industry conferences...

During February, the number of shares and votes in Mendus AB (publ) has changed as a result of 773,017 new shares being issued to Negma Group upon conversion of convertible bonds. The issue of shares...

“We are very happy with the progress we have made on all fronts in 2022 and the continued commitment of our entire team to develop impactful new cancer therapies. For 2023, we have taken necessary steps to focus on our most value-generating projects...

The INN name “vididencel” was selected by the World Health Organization’s International Nonproprietary Names Expert Committee and we will increasingly use it in all our materials.

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has requested the first tranche of a...